Skip to main content
OpenTrials
Completed

NCT Number: NCT02713542

Autologous Conditioned Plasma (ACP) Intra-articular (IA) Injections for Knee Osteoarthritis (OA)

This study is primarily investigating the effectiveness of Autologous Conditioned Plasma (ACP) Intra-articular (IA) in patients with Osteoarthritis (OA) in the knee.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Rush University Medical Center, Chicago, Illinois, United States

Loading trial locations.

About this study

This study is a prospective, multi center randomized double blind, two arm study.

90 subjects will be randomized to receive injections of either Autologous Conditioned Plasma Intra-articular or the control.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The subject is 18 to 70 years of age.
  • The subject presents with complaints of continued pain of primary knee for at least 6 weeks.
  • The subject has documented radiographs evidence of Osteoarthritis (OA) in the tibio-femoral or patella-femoral compartment of the target knee (Kellgren-Lawrence Grades II-III), using radiographs performed within 24 weeks of screening.
  • The subject has a WOMAC pain score of at least 8 out of 20 and at least moderate pain (a score of 2) for at least 2 questions on activities

Exclusion criteria

  • Grade I and IV on the knee Kellgren-Lawrence grading scale
  • Subject has clinically 3+ effusion of the target knee (stroke test grading system).
  • Subject has significant (> 10⁰) valgus or varus deformities as evidenced by standard of care X-ray.
  • Subject has had systemic or IA injection of corticosteroids in any joint within three months prior to screening.
  • Viscosupplementation in any joint in the past six months.
  • Subject has an increased risk for post- procedure bleeding (e.g., bleeding disorder or taking anticoagulants except low-dose aspirin).
  • Subject had prior open surgery on the target knee within 12 months or knee arthroscopy within 6 months
  • Subject has inflammatory disease of either knee other than OA.
  • Subject with underlying medical conditions that could interfere with the evaluation of the outcome.
  • Subject with positive pregnancy test, or breast feeding.
  • Subject with plans to participate in other clinical trial involving medical or surgical intervention in the next 12 months.
  • Subject with any condition (including cognitive impairment) that, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
  • Subject has rheumatoid arthritis or gout
  • Subject has a history of or a current infection at the affected joint.
  • Subject with plans to undergo any elective orthopedic surgery in the next 12 months.
  • Subject requires pain management therapy (with the exception of acetaminophen) not related to the target knee.

Treatment and study plan

ACP

Device

Autologous Conditioned Plasma

Placebo

Other

Three Normal Saline IA injections of 3-8 mL at 1-week intervals.

Other names: Normal Saline

Primary outcomes

  1. Pain Scores Measured by Western Ontario and McMaster Universities Index (WOMAC) Survey

    Time frame: 6 month visit

    The WOMAC Pain score will be used to measure outcome, the score ranges from 0 to 20. The higher the score indicates greater pain.

Sponsors and collaborators

Lead sponsor

Arthrex, Inc.

Industry

Registry information

Important dates

Study start
2016
Primary completion
2018
Study completion
2018
First posted
Mar 18, 2016
Registry last updated
Aug 13, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.